Program
delpacibart zotadirsen
In Novartis’s pipeline, PMO mediated exon 44 skipping
. Its studies are mostly in Muscular Dystrophy, Duchenne · Myotonic Dystrophy, led by Novartis.
Furthest: phase 3, since May 8, 20263 company-led studies, 2 open or runningNext primary completion: Apr 30, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 32 open or running | phase 3since May 8, 2026 | Dec 6, 2022 | Apr 30, 2027phase 2 · NCT06244082 |
- Named in Novartis’s own pipeline as
KPE179 (del-zota)
, phase 4, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 6, 2022First study: phase 2 study in Muscular Dystrophy, DuchenneFirst studyNCT05670730 · 70 enrolled · United States
- Jan 26, 2024Phase 2 study in Muscular Dystrophy, DuchenneNCT06244082 · 39 enrolled · United States
- May 8, 2026Phase 3 study in Muscular DystrophiesPhase 3 reachedNCT07587242 · 70 planned · Australia, Belgium, Canada and more
Ahead
- Apr 30, 2027Primary completion: phase 2 study in Muscular Dystrophy, DuchenneNCT06244082
- May 2029Primary completion: phase 3 study in Muscular DystrophiesNCT07587242
TargetBeta
“PMO mediated exon 44 skipping”the company's pipeline, read by Claude · source
Other programs on DMD
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| delandistrogene moxeparvovecrule | Sarepta Therapeutics | phase 4 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07587242Muscular Dystrophies · Australia, Belgium, Canada and more | 3 | Recruiting | May 2029 | 70 |
| NCT06244082Muscular Dystrophy, Duchenne · United States | 2 | Active, not recruiting | Apr 30, 2027 | 39 |
| NCT05670730Muscular Dystrophy, Duchenne · United States | 2 | Completed | Nov 25, 2024 | 70 |
How it is read
Names in the registry
- “AOC 1044”, 3 entries
Conditions, from the studies’ own filings
- Muscular Dystrophy, Duchenne, 2 studies
- Myotonic Dystrophy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.